Sarepta shares slump on DMD trial update

12 January 2022
sarepta-big

Shares in US biotech Sarepta Therapeutics (Nasdaq: SRPT) lost 19% of their value on Monday and Tuesday following the presentation of new trial results at the 40th Annual JP Morgan Healthcare Conference.

Sarepta announced top-line results from Part 2 of the study SRP-9001-102, an ongoing, randomized, double-blind, placebo-controlled trial to evaluate the safety, efficacy and tolerability of a single dose of SRP-9001 (delandistrogene moxeparvovec) in 41 patients with Duchenne muscular dystrophy (DMD), 21 of whom were in the placebo crossover cohort.

"SRP-9001 is the greatest near-term hope we all have to address the need for a therapy that changes the trajectory of this disease"This investigational gene transfer therapy is intended to deliver its micro-dystrophin-encoding gene to muscle tissue for the targeted production of the micro-dystrophin protein. SRP-9001-treated participants from the placebo crossover group scored a statistically-significant 2.0 points higher on the mean North Star Ambulatory Assessment (NSAA) at 48 weeks compared to propensity-score weighted external controls.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology